Solid tumors—whether sequestered deep within the abdomen or tucked into the recesses of the skull— are surrounded by healthy tissue. This means that when clinicians take a biopsy of the tumor and send it for sequencing to see which drugs will fight it most effectively, some non-tumor DNA gets mixed in with the tumor’s.
“You have to have a certain amount of tumor DNA relative to the non-tumor DNA to get a clinical result, and that number is 30 percent,” explained John Butler, the co-founder and chief executive officer of QuantumCyte, a medical technology company. The problem is that in 25 percent of tumor biopsies, there’s not enough tumor DNA.

John Butler is the cofounder and CEO of QuantumCyte.
QuantumCyte
“Those patients are not even getting a shot at finding a targeted therapy,” said Butler. “Every single reference lab in the world that does solid tumor testing suffers from this problem.”
To overcome this challenge, Butler and his colleagues at QuantumCyte developed an artificial intelligence-guided digital pathology tool that identifies the borders of a tumor on a biopsy slide and prints a polymer mask on top of healthy tissue. This leaves just the tumor cells from which researchers can isolate tumor DNA and sequence it. By enriching the amount of pure tumor DNA in a sample, clinicians can give more patients greater insight into which drugs will treat their cancer best.
Masking Healthy Tissue to Highlight Tumor Cells
Butler, who has worked in the genomics industry for his whole career, didn’t initially set out to solve this low tumor purity problem. His wife had been diagnosed with late-stage metastatic cancer. While she has now been progression free for multiple years, her diagnosis spurred Butler to look for new ways to identify drugs specific to a patient’s particular cancer-driving mutations that could slow metastatic disease progression.
However, when he spoke with Tony Lim, the chair of Pathology at Singapore General Hospital, about his idea, Lim had some honest feedback for him.
“He said, ‘That's really cool, but you're solving the wrong problem,’” Butler said. Lim told him about the issue of tumor purity in tissue biopsies. It was not a genomic issue to overcome, but a physical one.
To solve this problem, the team developed the QCPRECISE™ Precision Extraction Platform. The system uses available artificial intelligence models to identify the tumor within the biopsy. The researchers at QuantumCyte developed software that converts the digital image of the biopsy into a high-resolution black and white image, where black denotes healthy tissue and white represents tumor cells.

QuantumCyte’s QCPRECISE™ Precision Extraction Platform prints a semi-solid plastic-polymer that solidifies almost instantly onto healthy tissue, leaving just tumor tissue uncovered.
QuantumCyte
“To do that translation is actually pretty complex and takes a lot of learning,” Butler said. “It's taken us a while to get the system to work simply because it was a hard problem to solve. Also, we needed computational power that didn't exist in 2019 when we came up with the idea.”
The researchers then developed a plastic-based ink that they print onto the black-noted spaces of the pathology slide, masking the healthy tissue and leaving just the tumor accessible. To isolate the tumor DNA, the team dissolves the tumor cells with a solution, pipettes up the DNA, and then sends that DNA for sequencing.
In a study the team ran with Lim at Singapore General Hospital, they ran their process side-by-side with the conventional pathology workflow and found multiple cases where the traditional process did not have enough DNA while theirs did.
“We have cases where patients who wouldn't otherwise even have their tumor sequenced, [and] we have found them markers for immunotherapy, and they've received the therapy that they need,” Butler said. Additionally, Butler and his team have found that even for patients’ whose biopsies had enough DNA for sequencing, their technology allowed them to identify additional markers for more drugs that could target their specific tumor.
For example, in a sample from a patient with colon cancer, “We found a marker for a colon cancer drug, and the current [pathology] process found the same marker. But we found another marker for a breast cancer drug,” Butler said. “This patient has a lot of confidence that the drug will work for them, but they also have more information on how they might treat their disease.”

Surekha Karudapuram is the Chief Product Officer at QuantumCyte.
QuantumCyte
Additionally, the team has found that with their workflow, they don’t need a lot of tumor DNA, just a highly purified sample. This means that patients’ biopsies can undergo different tests to give clinicians more insight into how to treat their patients.
“[It’s] the whole idea of having multiomic data,” said Surekha Karudapuram, QuantumCyte’s chief product officer. “Now you have more tissue to do more analysis beyond genomics.”
Taking Pathology Into the Future
QuantumCyte was recently named one of four BioTools Innovator finalists, which was very exciting, Butler said. “Anytime we have the opportunity to discuss and show a large number of people what we're doing, it increases the chances that patients and oncologists will see what we're doing and start to ask questions,” he added.
In fact, Butler already gets queries from patients whose biopsies have too little tumor material to be sequenced. While QuantumCyte can’t help them yet, the team is working with Quest Diagnostics to get their technology clinically validated so that more patients can get their tumors analyzed.

Surekha Karudapuram (left) and John Butler (center) of QuantumCyte, a 2026 BioTools Innovator finalist, attended the BioTools Innovator Capstone event in San Diego.
BioTools Innovation
While QuantumCyte is currently focused on isolating tumor DNA for sequencing, their technology platform can also isolate RNA and protein. They are also looking at applications beyond oncology and have also tested their platform in inflammatory bowel disease and fatty liver disease.
“My drive in my entire career has been: How do I accelerate biology to impact the highest number of people? And we're now at that stage where we can do that,” Butler said. “Any solid tissue disease can leverage our technology.”
















